Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks
•To measure the blood concentrations of pimecrolimus after single and repeated doses of Elidel (pimecrolimus) Cream 1% when applied twice daily for 3 weeks on the whole lesional skin in patients with ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals UK Limited (UK)
Update Il y a 5 ans
Combination therapy of Visudyne, Minocycline, Dexamethasone and Ranibizumab (VIMDER) for the treatment of subfoveal choroidal neovascularisation (CNV)
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
Novartis CLBH589E2214 : Essai de phase 2 évaluant le panobinostat, chez des patients ayant un lymphome de Hodgkin en rechute ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase II study of oral panobinostat in adult patients with relapsed/refractory classical Hodgkin's lymphoma after failure of high-dose chemotherapy with autologous stem cell transfusion and a gemcit...
Country
France
organs
Lymphomes hodgkinien (maladie de Hodgkin)
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 5 ans
A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD)
To demonstrate that QVA149 (110/50 μg o.d.) is superior to NVA237 (50 μg o.d.) with regard to the rate of moderate to severe COPD exacerbations during 52 weeks of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with amlodipine 10 mg in patients with essential hypertension not adequately responsive to amlodipine 10 mg monotherapy
Demonstrate the efficacy of the combination therapies of aliskiren/amlodipine (150/10 mg and 300/10 mg), in hypertensive patients who do not adequately respond to a 4-week treatment of amlodipine 10 m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
CLDK378A2301 : Essai de phase 3 randomisé, comparant l’efficacité le LDK378 par voie orale à une chimiothérapie standard, chez des patients ayant un cancer du poumon non à petites cellules non épidermoïdes avec un réarrangement du gène ALK (ALK positif) de stade IIIB ou IV, non traités précédemment. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité et la sécurité d’emploi du LDK378 à une chimiothérapie standard, chez des patients ayant un cancer du poumon non à petites cellules avec un réarran...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients
To assess the effect of MEK162 when administered b.i.d. for 6 months, on cardiac hypertrophy in Noonan syndrome patients with confirmed hypertrophic cardiomyopathy
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 5 ans
A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg) delivered via a multiple dose inhaler and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD)
To evaluate the bronchodilatory efficacy of QAB149 delivered via the MDDPI in patients with COPD
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma
To assess the safety and tolerability of Glivec in combination with Vinorelbine in patients with progressive or metastatic breast cancer after previous anthracycline chemotherapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
18
19
20
21
22
23
24
25
26
27
Next